BrainStorm Cell Therapeutics Inc. (BCLI) - NASDAQ
  • Mon, Jan. 11, 6:52 PM
    • BrainStorm Cell Therapeutics (NASDAQ:BCLI) has posted "highly promising" data published in JAMA Neurology's issue out today. It indicated that a new treatment for amyotrophic lateral sclerosis (a k a Lou Gehrig's disease) developed by the company significantly slowed the progression of the disease.
    • The findings involved the Phase 1/2 and Phase 2a clinical trials, which began in 2011 and involve a stem cell infusion protocol. A phase 2 double blind study is running currently using an identical protocol.
    • The company had postponed a conference call with "important developments" from Dec. 16 to today because of a longer than expected embargo. Adam Feuerstein called the findings recycled and "highly promotional."
    • Shares fell 22.4% today on more than five times normal (thin) volume.
    | Mon, Jan. 11, 6:52 PM | 4 Comments
  • Apr. 21, 2015, 9:22 AM
    | Apr. 21, 2015, 9:22 AM
  • Apr. 21, 2015, 9:16 AM
    • Data presented at a poster session at the 67th Annual Meeting of the American Academy of Neurology show that amyotrophic lateral sclerosis (ALS) patients treated with Brainstorm Cell Therapeutics' (NASDAQ:BCLI) NurOwn stem cells demonstrated a statistically significant improvement in the rate of decline of their illness, measured by changes in Forced Vital Capacity (FVC) and ALS Functional Rating Score-Revised (ALSFRS-R).
    • The effects of intramuscular injection of NurOwn were reported for the first time. 3D volumetric analysis using MRI showed an improvement in the rate of decline in muscle mass in the right arm (site of administration) through one month post-treatment compared to the left arm.
    • A U.S. Phase 2 study is now more than 50% enrolled with a multi-dose trial in the planning stage.
    • Shares are up 11% premarket on robust volume.
    | Apr. 21, 2015, 9:16 AM | 1 Comment
  • Apr. 20, 2015, 12:47 PM
    | Apr. 20, 2015, 12:47 PM | 4 Comments
  • Apr. 14, 2015, 9:52 AM
    • Thinly-traded nano cap Brainstorm Therapeutics (BCLI +7.2%) gaps up this morning in response to its announcement that it will present results next week from a Phase 2a study evaluating NurOwn in patients with amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. The presentation is scheduled for the morning of Tuesday, April 21, during the American Academy of Neurology annual meeting in Washington, D.C.
    • Traders appear to anticipate good news. In January, the stock briefly tripled after the company announced positive preclinical results for NurOwn cells in a mouse model of autism.
    • NurOwn cells are mesenchymal stem cells that have been induced, via the company's proprietary methods, to secrete a variety of neurotrophic factors.
    • Previously: Brainstorm up on preclinical results (Jan. 26)
    | Apr. 14, 2015, 9:52 AM
  • Apr. 14, 2015, 9:12 AM
    | Apr. 14, 2015, 9:12 AM
  • Jan. 26, 2015, 9:14 AM
    | Jan. 26, 2015, 9:14 AM
  • Jan. 26, 2015, 9:09 AM
    • Giddy traders propel nano cap Brainstorm Cell Therapeutics (NASDAQ:BCLI) up 11% premarket on robust volume in response to its announcement of positive preclinical results for NurOwn cells in the BTBR mouse model of autism. Treatment with NurOwn demonstrated marked behavioral benefits in BTBR mice after a single treatment. The results are encouraging but a colossal amount of development work lies ahead to validate the efficacy of NurOwn in humans for this indication.
    • NurOwn cells are mesenchymal stem cells that have been induced, via the company's proprietary methods, to secrete a variety of neurotrophic factors.
    | Jan. 26, 2015, 9:09 AM
  • Jan. 5, 2015, 12:48 PM
    | Jan. 5, 2015, 12:48 PM
  • Jan. 5, 2015, 11:56 AM
    • Recent IPO Brainstorm Cell Therapeutics (BCLI -20.8%) retraces some of its recent up move on a 10x surge in volume. Shares tripled from the December 15 low of $2.81 in response to the announcement of positive results for NurOwn in ALS.
    • This morning's conference call about the data failed to sustain the momentum.
    • Previously: Brainstorm Cell up on clinical trial results (Dec. 31, 2014)
    | Jan. 5, 2015, 11:56 AM | 3 Comments
  • Jan. 5, 2015, 9:10 AM
    | Jan. 5, 2015, 9:10 AM
  • Jan. 2, 2015, 12:50 PM
    | Jan. 2, 2015, 12:50 PM
  • Jan. 2, 2015, 9:14 AM
    | Jan. 2, 2015, 9:14 AM | 6 Comments
  • Jan. 2, 2015, 8:27 AM
    • Recent IPO Brainstorm Therapeutics (NASDAQ:BCLI) is up 43% premarket on robust volume in response to its report of positive results for NurOwn in patients with amyotrophic lateral sclerosis (ALS) or Lou Gehrig's Disease. The company will host a conference call on Monday to discuss the data.
    • Previously: Brainstorm Cell up on clinical trial results (Dec. 31, 2014)
    | Jan. 2, 2015, 8:27 AM | 1 Comment
  • Dec. 31, 2014, 1:05 PM
    | Dec. 31, 2014, 1:05 PM
  • Dec. 31, 2014, 10:25 AM
    • Thinly-traded nano cap Brainstorm Cell Therapeutics (BCLI +22.7%) jumps on a 6x surge in volume in response to CEO Tony Fiorino's positive comments about the final results from the Phase 2a study of NurOwn in ALS patients.
    • Management will host a conference call on January 5 at 8:30 am ET to discuss the data.
    • Previously: BrainStorm to start Phase 2 ALS trial (April 28)
    • Stem cell-related tickers: (CUR +3.8%)(STEM)(NBS +0.5%)(OTCQB:ISCO +1.4%)(PSTI +2.2%)(OTCQB:NVIV -1.5%)(FCSC +1.6%)
    | Dec. 31, 2014, 10:25 AM
Company Description
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops innovative adult stem cell therapeutic products. It currently focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for... More
Sector: Healthcare
Industry: Biotechnology
Country: United States